A detailed history of Legal & General Group PLC transactions in Denali Therapeutics Inc. stock. As of the latest transaction made, Legal & General Group PLC holds 143,937 shares of DNLI stock, worth $4.24 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
143,937
Previous 107,450 33.96%
Holding current value
$4.24 Million
Previous $2.2 Million 51.63%
% of portfolio
0.0%
Previous 0.0%

Shares

26 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$14.96 - $23.22 $545,845 - $847,228
36,487 Added 33.96%
143,937 $3.34 Million
Q1 2024

May 14, 2024

BUY
$15.83 - $23.35 $11,666 - $17,208
737 Added 0.69%
107,450 $2.2 Million
Q4 2023

Feb 15, 2024

BUY
$16.2 - $23.18 $14,385 - $20,583
888 Added 0.84%
106,713 $2.29 Million
Q3 2023

Nov 14, 2023

BUY
$20.63 - $30.17 $19,247 - $28,148
933 Added 0.89%
105,825 $2.18 Million
Q2 2023

Aug 14, 2023

BUY
$23.37 - $32.96 $169,993 - $239,751
7,274 Added 7.45%
104,892 $3.1 Million
Q1 2023

May 15, 2023

BUY
$21.91 - $32.67 $57,031 - $85,040
2,603 Added 2.74%
97,618 $2.25 Million
Q4 2022

Feb 14, 2023

BUY
$26.28 - $33.92 $236,467 - $305,212
8,998 Added 10.46%
95,015 $2.64 Million
Q3 2022

Nov 14, 2022

SELL
$25.97 - $38.53 $12,621 - $18,725
-486 Reduced 0.56%
86,017 $2.64 Million
Q2 2022

Aug 22, 2022

BUY
$20.88 - $35.19 $147,767 - $249,039
7,077 Added 8.91%
86,503 $2.55 Million
Q1 2022

May 16, 2022

BUY
$29.0 - $47.27 $13,195 - $21,507
455 Added 0.58%
79,426 $2.56 Million
Q4 2021

Feb 14, 2022

BUY
$42.59 - $55.02 $61,457 - $79,393
1,443 Added 1.86%
78,971 $3.52 Million
Q3 2021

Nov 15, 2021

BUY
$48.48 - $78.23 $740,968 - $1.2 Million
15,284 Added 24.55%
77,528 $3.91 Million
Q2 2021

Aug 12, 2021

BUY
$50.3 - $78.44 $940,308 - $1.47 Million
18,694 Added 42.93%
62,244 $4.88 Million
Q1 2021

May 17, 2021

SELL
$53.8 - $81.53 $72,468 - $109,820
-1,347 Reduced 3.0%
43,550 $2.49 Million
Q4 2020

Feb 12, 2021

BUY
$36.89 - $93.56 $195,922 - $496,897
5,311 Added 13.42%
44,897 $3.76 Million
Q3 2020

Nov 13, 2020

BUY
$23.13 - $38.84 $111,764 - $187,674
4,832 Added 13.9%
39,586 $1.42 Million
Q2 2020

Aug 14, 2020

BUY
$16.01 - $28.82 $135,700 - $244,278
8,476 Added 32.26%
34,754 $840,000
Q1 2020

May 14, 2020

SELL
$14.2 - $27.98 $19,610 - $38,640
-1,381 Reduced 4.99%
26,278 $460,000
Q4 2019

Feb 13, 2020

BUY
$14.4 - $19.99 $26,798 - $37,201
1,861 Added 7.21%
27,659 $482,000
Q2 2019

Aug 14, 2019

BUY
$18.5 - $28.14 $9,065 - $13,788
490 Added 1.94%
25,798 $536,000
Q1 2019

May 15, 2019

BUY
$17.99 - $24.65 $299,893 - $410,915
16,670 Added 192.98%
25,308 $587,000
Q4 2018

Feb 15, 2019

BUY
$13.88 - $21.75 $16,822 - $26,361
1,212 Added 16.32%
8,638 $179,000
Q3 2018

Nov 20, 2018

SELL
$12.46 - $21.74 $81,662 - $142,483
-6,554 Reduced 46.88%
7,426 $162,000
Q2 2018

Aug 10, 2018

SELL
$15.25 - $21.02 $575,779 - $793,631
-37,756 Reduced 72.98%
13,980 $213,000
Q1 2018

May 17, 2018

BUY
$15.36 - $24.8 $793,820 - $1.28 Million
51,681 Added 93965.45%
51,736 $1.02 Million
Q4 2017

Feb 13, 2018

BUY
$15.04 - $21.45 $827 - $1,179
55
55 $1,000

Others Institutions Holding DNLI

About Denali Therapeutics Inc.


  • Ticker DNLI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 134,174,000
  • Market Cap $3.95B
  • Description
  • Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...
More about DNLI
Track This Portfolio

Track Legal & General Group PLC Portfolio

Follow Legal & General Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Legal & General Group PLC with notifications on news.